Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an undisclosed amount of money in a Series B1 financing round. The round was solely led by AstraZeneca and CICC’s first joint global medical fund. Proceeds will be used to expand its product pipeline for women’s and infant products, its cancer testing product pipeline, and to support regulatory filings, manufacturing, and commercialization in China and the US.
Company Overview
Founded in 2015, mProbe has established research and development (R&D) centers and GMP-compliant facilities in Maryland and California in the United States, as well as in Shanghai, Tianjin, Chengdu, and other locations in China. Additionally, the company owns a CAP/CLIA clinical laboratory certified by the College of American Pathologists and the American Board of Clinical Laboratories in Maryland, US.-Fineline Info & Tech
